Meeting
2020 ASCO Virtual Scientific Program
Health-related quality of life (HRQoL) in the phase III QUAZAR-AML-001 trial of CC-486 as maintenance therapy for patients with acute myeloid leukemia (AML) in first remission following induction chemotherapy (IC).
Authors
Gail J. Roboz
Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY
Gail J. Roboz , Hartmut Dohner , Christopher Pocock , Hervé Dombret , Farhad Ravandi , Jun Ho Jang , Dominik Selleslag , Jiri Mayer , Uwe Marc Martens , Jane Liesveld , Teresa Bernal del Castillo , Ming-Chung Wang , Ignazia La Torre , Barry Skikne , Keshava Kumar , Qian Dong , Julia Braverman , Salem Abi Nehme , C. L. Beach , Andrew Wei
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT01757535
Citation
J Clin Oncol 38: 2020 (suppl; abstr 7533)
DOI
10.1200/JCO.2020.38.15_suppl.7533
Abstract #
7533
Poster Bd #
306
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
CC-486 is safe and well-tolerated as maintenance therapy in elderly patients (≥75 years) with acute myeloid leukemia (AML) in first remission following induction chemotherapy: Results from the phase III QUAZAR AML-001 trial.
First Author: Farhad Ravandi
Poster
2023 ASCO Annual Meeting
Health related quality of life (HRQoL) in patients with triple-class-exposed relapsed/refractory multiple myeloma (TCE RRMM) treated with idecabtagene vicleucel (ide-cel) versus standard regimens: Patient-reported outcomes (PROs) from KarMMa-3 phase 3 randomized controlled trial (RCT).
First Author: Michel Delforge
Poster
2020 ASCO Virtual Scientific Program
Escalated dosing schedules of CC-486 for patients experiencing first acute myeloid leukemia (AML) relapse: Results from the phase III QUAZAR AML-001 maintenance trial.
First Author: Hartmut Dohner
Poster
2018 Palliative and Supportive Care in Oncology Symposium
Risk of health-related quality-of-life events and pulmonary toxicities in patients with cancer treated with poly adenosine diphosphate ribose polymerase inhibitors: A meta-analysis of seven phase III trials.
First Author: Sriman Swarup